Solutions

Online Inquiry

Solutions

According to industry analysts, the U.S. cancer therapeutics market size is expected to reach around US$ 112.25 billion by 2032 from at US$ 45.92 billion in 2022, representing at a CAGR of 9.40% between 2023 to 2032. This surge in market size underscores the increasing demand for effective and innovative therapy solutions for cancer.

Alfa Cytology is a cutting-edge biotech-company that excels in cancer therapy development and preclinical research. Our skilled team of scientists, bioinformatics experts, and oncologists is dedicated to providing innovative cancer therapeutics discovery & development and preclinical research service to advance the field of oncology.

By Diseases

By Targets

By Molecule Types

By Services

We provide our clients with up-to-date research findings and actionable insights in different areas of cancer.

Nervous System Cancer

As a leading Preclinical CRO, Alfa Cytology has established a strong track record in the development of innovative inhibitors against diverse cancer targets. Our team of seasoned researchers and drug discovery experts is dedicated to uncovering novel therapeutic strategies that disrupt the fundamental processes driving cancer growth, progression, and metastasis.

Immune Checkpoint Inhibitor

PD-1 Inhibitor
PD-L1 Inhibitor
CTLA-4 Inhibitor

Metabolic Inhibitor

Adenosine Pathway Inhibitor
Kynurenine Pathway Inhibitor

Protein Kinase Inhibitor

EGFR Inhibitor
HER2 Inhibitor
ALK Inhibitor

Autophagy Inhibitor

VPS34 Inhibitor
ATG Inhibitor
mTOR Inhibitor
Beclin 1 Inhibitor

Modulation of TAM

AXL Inhibitor
MER RTK Inhibitor
TYRO3 Inhibitor

Cytokine and Chemokine Pathway Inhibitor

TNF-α Inhibitor
IL-1 Inhibitor
IL-6 Inhibitor

IAP Inhibitor

XIAP Inhibitor
cIAP1 Inhibitor
NF-κB Pathway Inhibitor

Modulation of NK Cell

NKG2A
KIR

Cancer Growth Inhibitor

CDK Inhibitor
VEGF–VEGFR Inhibitor
PARP Inhibitor

Cancer Stem Cell Inhibitor

CDK Inhibitor
Notch Inhibitor
Wnt Inhibitor

At Alfa Cytology, we recognize that the development of effective cancer treatments requires a diverse and innovative approach. As such, we offer a comprehensive range of therapeutic agent platforms to support the discovery and optimization of novel cancer therapies, including:

Small Molecule Development Platform

Cell Therapy Development Platform

Antibody Development Platform

Peptide Development Platform

Cancer Vaccine Development Platform

Gene Therapy Development Platform

With innovative technologies and advance platforms, our experienced team provides customized and one-stop solutions to meet specific requirements of the clients in timely and cost-effective manner.

Therapy Development

Diagnostic Development

Modeling Services

Preclinical Research

Why Choose US?

Extensive Experience

Our extensive experience will provide you with a streamlined, efficient, and quality-assured development process.

Advanced Facilities

Our laboratory is equipped with multiple advanced experimental equipment, which is helpful for cancer vaccine development.

Customized Cooperation

Our team works closely with you to design a complete plan for cancer vaccine development and customize exclusive services.

Timely and Efficient Delivery

We are committed to delivering results in a timely manner without compromising quality.

Contact Us

Alfa Cytology is a cutting-edge biotech company that provides innovative cancer therapeutics discovery & development platforms, rich models, and one-stop preclinical research service for pharmaceutical companies and researchers. If you have any questions or require further information, please do not hesitate to contact us.

! For research use only.